Ivacaftor (Kalydeco®) for the treatment of CF patients with the R117H mutation.

Assessment Status Assessment process complete
Drug Ivacaftor
Brand Kalydeco®
Indication For the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene.
Assessment Process
Rapid review commissioned 14/01/2016
Rapid review completed 10/02/2016
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 15/04/2016
NCPE assessment completed 05/01/2017
NCPE assessment outcome Reimbursement not recommended at the submitted price

Technical Summary

The HSE has approved reimbursement following confidential price negotiations.